VANCOUVER, British Columbia, Canada – Zymeworks Inc., a privately held biotherapeutics company focused on the development of best-in-class antibody and next generation protein-based therapeutics, announced today with great sadness that Dr. Patrick McCroskey, PhD, lost his fight against cancer.
“The entire Zymeworks family would like to pass along our deepest sympathies and condolences to Patrick's family, and to his coworkers at TPG Biotech®” says Dr. Ali Tehrani, Zymeworks’ President and CEO. “Patrick was Zymeworks’ first independent board member, and joined Zymeworks at an important time as we began the transition from industrial biotechnology towards biotherapeutics. He saw the potential and believed in both our technology and the people at Zymeworks. Moreover, his guidance and counsel were of great personal value, and his values and perspective influenced our many aspects of the Company throughout his six years serving on our Board”.
“Patrick’s friendship and wise counsel will be missed by everyone who had the pleasure of knowing and working with him” says Nick Bedford, Zymeworks’ Chairman, “and his generous support in Zymeworks’ formative years has helped make Zymeworks the Company it is today.”
Dr. McCroskey’s influence will be felt for years to come in the direction and advances made by Zymeworks. For everyone in the Company, Zymeworks’ ongoing efforts to develop best-in-class therapeutics will be linked to his loss. A donation to the BC Cancer Agency has also been made in Dr. McCroskey’s name.
Dr. McCroskey joined Zymeworks’ Board of Directors after serving as Vice-President of Business Development at Diversa Corporation (now Verenium), and he continued serving on Zymeworks board as an independent board member after joining TPG Biotech®, the life science venture investment arm of TPG (formerly known as Texas Pacific Group®). Dr. McCroskey had also served as the Chief Financial Officer of Ceres, Inc., and as Vice President of Finance and Strategic Planning for Intarsia Corporation. Dr. McCroskey also served on the boards of AgraQuest, Inc. and Genomatica, Inc., and was a board observer at Elevance Renewable Sciences, Inc., Draths Corporation and PatientSafe Solutions. Dr. McCroskey held a Ph.D. in Chemical Engineering from Carnegie Mellon University.
Zymeworks is a privately held biotechnology company that is developing best-in-class antibody therapeutics for the treatment of oncology, autoimmunity and inflammatory diseases. The company’s proprietary ZymeCAD™ structure-guided protein engineering technology and its novel Azymetric™ and AlbuCORE™ platforms enable the development of highly potent bi-specific antibodies and multivalent protein therapeutics targeted across a range of indications. Zymeworks is focused on growing its preclinical biotherapeutics pipeline through in-house research and development programs and strategic collaborations. More information on Zymeworks can be found at http://www.zymeworks.com.
Dr. Ali Tehrani, Ph.D.
President & CEO